ANNUAL REPORT - Pevion Biotech AG
ANNUAL REPORT - Pevion Biotech AG
ANNUAL REPORT - Pevion Biotech AG
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
attributed to these vaccines. Since the target population is quite large<br />
already, rare side effects will propagate often. <strong>Pevion</strong> <strong>Biotech</strong>’s DiTe vaccine<br />
will show a more favorable side effect profile than the currently marketed<br />
products. The vaccine will be reformulated and will enter preclinical<br />
development in Q1 2007.<br />
<strong>Pevion</strong> <strong>Biotech</strong>_Annual Report2005_01_01_04_004 12/13
Change language